🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB

RecruitingPhase 4Ages 18 Years - 65 YearsAllShanghai Pulmonary Hospital, Shanghai, China
NCT05493267 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

A Exploratory Study of drug combination (zoledronic acid/interleukin 2) that specifically amplifies Vγ2Vδ2 T cells in combination with anti-tuberculosis chemotherapy for the treatment of MDR-TB.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * RR-TB/MDR-TB (resistant to at least isoniazid and rifampicin). * Poor efficacy of the original treatment regimen or no response to treatment or less than 4 effective drugs. Exclusion Criteria: * Immunosuppression due to co-morbidities, such as immune system disorders, tumors, etc. * Test confirms poor response to ZOL and IL-2 stimulation.
💊

What it tests

  • Vγ2Vδ2 T lymphocyte-based immunotherapy
  • Treatment regimens for MDR-TB
📍

Where

2 sites
Shanghai Pulmonary Hospital, Shanghai, China
Shanghai, China
Shanghai Pulmonary Hospital
Shanghai, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy